Ju Fu Tang Biotech Holdings Co., Ltd. (JU FU TANG BIOT) filed its Monthly Return for July 2026 with Hong Kong Exchanges and Clearing Limited, confirming stability in both authorised and issued share capital.

Authorised/Registered Capital • Authorised share count remained at 500.00 million ordinary shares. • Par value stayed at HKD 0.16, keeping total authorised capital unchanged at HKD 80.00 million.

Issued Shares and Public Float • Issued shares (excluding treasury shares) were unchanged at 301.86 million. • No treasury shares were held or cancelled during the month. • The company affirmed compliance with the minimum 25% public-float requirement under GEM Rule 17.37D(1).

Share Option Movements • 10.70 million options under the 24 March 2016 scheme (HKD 0.315 exercise price; expiry 11 July 2026) lapsed during the month, leaving a nil balance for that grant. • 9.14 million options (HKD 0.163 exercise price; expiry 17 March 2027) remain outstanding, with no exercises recorded in July. • No new shares were issued and no treasury shares were transferred pursuant to option exercises.

Other Equity Instruments • The company reported no activity in warrants, convertible securities, or other share issuance agreements. • No additional share repurchases, redemptions, or treasury-share transactions occurred.

Regulatory Compliance • The filing includes confirmations of compliance with all applicable listing rules, legal requirements, and receipt of all monies due for past issuances.

Overall, Ju Fu Tang Biotech’s equity structure was static in July 2026, with the only notable event being the expiry and lapse of 10.70 million share options.